Company: ACBM
Filing Date: 2025-11-10
Form Type: 10-Q
Source: 0001640334-25-001999
Chunk: 40

Company: ACRO BIOMEDICAL CO., LTD.
Filing Date: 2025-11-10
Form: 10-Q
Item: Item 8
Chunk 40
---
 in accounts payable and accrued expenses of $35,563 and increased by imputed interest – related parties of $6,025 and security deposit of $2,285.

Cash used in operating activities of $26,177 for the nine months ended September 30, 2024 reflected primarily our net loss of $31,624, increased primarily by imputed interest of $3,134, a reduction of prepaid expenses of $1,250 and by an increase in accounts payable and accrued expenses of $1,063.

Cash provided by financing activities for the nine months ended September 30, 2025 and 2024 reflected advances from a minority stockholder. These advances provided us with funds to cover our cash used in operations.

 13Table of Contents

Going Concern

The accompanying financial statements have been prepared assuming that we will continue as a going concern, which contemplates the realization of assets and the liquidation of liabilities in the normal course of business. We had minimal cash as of September 30, 2025, we have had no revenue subsequent to December 31, 2022 through the date of this report, and we incurred a loss from operations for the nine months ended September 30, 2025, the years ended December 31, 2024 and 2023 as well as prior years, had negative cash flow from operations for the nine months ended September 30, 2025 and the years ended December 31, 2024 and 2023. To date, we did not generate any revenue subsequent to December 31, 2022 and did not develop any products from our research and development activities during the period from May 2021 through August 2023.  Further, our common stock is presently traded on the OTC Market Group’s Pink Limited Market.  Our common stock was previously listed on the OTC Market Group’s Expert Market, as a result of which our common stock was not eligible for proprietary broker-dealer quotes.  There are no market makers for our common stock.  At present, our stock is not eligible for proprietary broker-dealer quotations and all quotes reflect unsolicited customer orders.  Unsolicited only stocks have a higher risk of wider spreads, increased volatility, and price dislocations. Investors may have difficulty selling this stock. An initial review by a broker-dealer under SEC Rule15c2-11 is required for brokers to publish competing quotes and provide continuous market making.  Accordingly, there are no published quotes for our common stock and